Risk of first-time major cardiovascular event among individuals with newly diagnosed type 2 diabetes: data from Danish registers
Authors' conclusion
Compared with well-controlled individuals on GLDT, individuals not on initial GLDT had a higher 5 year risk of MACE, even among those achieving remission of type 2 diabetes. This may be related to lower use of statins and RASi.
Study context
- Population
- Individuals with newly diagnosed T2D and a first measured HbA1c 48–57 mmol/mol (6.5–7.4%), 2014–2020, Danish registers
- Participants
- 14,221 individuals
- Exposure
- Initial omission of glucose-lowering drug treatment (GLDT) (remission or persistent T2D) and poorly controlled on GLDT vs well-controlled on GLDT
- Outcome
- Standardised risk of MACE
- Follow-up
- 5 year
Methodological detailsregistry-based
- Registry-based
Main finding
As reported in the abstract
Each group vs well-controlled on GLDTRisk difference (95% CI)
Persistent T2Dhigher with persistent T2D not on GLDT
3.3%(1.6–5.1)
Remissionhigher with remission not on GLDT
2.0%(0.4–3.7)
Poorly controlled on GLDT
3.5%(1.3–5.7)
Observational data: associations, not effects.
Further findings
Initiation of statins and renin-angiotensin system inhibitors (RASi)
- Fewer individuals not on GLDT initiated statins and RASi vs individuals on GLDT
Reduction in 5 year major adverse cardiovascular events (MACE) risk if statin and RASi initiation equalled well-controlled on GLDT
- Persistent T2D: possible risk reduction
- 2.1% (95% CI 1.2, 2.9)
- Remission: possible risk reduction
- 1.1% (95% CI 0.4, 1.9)
Original publication
Risk of first-time major cardiovascular event among individuals with newly diagnosed type 2 diabetes: data from Danish registers. Diabetologia. Published 2 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →